Literature DB >> 3539624

Pharmacokinetics of ceftazidime in patients with biliary tract disease.

R A Walstad, J N Wiig, E Thurmann-Nielsen, T B Halvorsen.   

Abstract

After administration of ceftazidime as a 1 g i.v. bolus injection, its concentration was measured by HPLC at frequent intervals in serum, bile and tissue from different parts of the biliary tract in 32 patients undergoing operation for biliary tract disease. In bile from the functioning gallbladder and common bile duct, a high concentration of ceftazidime was found, mean 18.5 and 26.6 mg/l, respectively. In bile from the non-functioning gallbladder, a very low concentration was found (less than 1.5 mg/l). Ceftazidime in the gallbladder wall varied considerably with the type and degree of inflammation judged histologically; the mean level was 21.3 mg/kg. The elimination half-life of ceftazidime was 1.74 h, apparent volume of distribution 20.01 and total plasma clearance 133 ml/min. In bile from T-tube specimens a high concentration was found, the mean peak values being 27.2 mg/l. However, biliary excretion of the drug was low at less than 0.5% of the administered dose. These concentrations of ceftazidime were sufficient to inhibit the in-vitro growth of pathogens, namely the Enterobacteriaecae commonly responsible for biliary tract infection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3539624     DOI: 10.1007/BF00981132

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Antibiotic treatment of biliary sepsis.

Authors:  M R Keighley; R B Drysdale; A H Quoraishi; D W Burdon; J Alexander-Williams
Journal:  Surg Clin North Am       Date:  1975-12       Impact factor: 2.741

2.  Bacteriological investigation of the biliary system and liver in biliary tract disease correlated to clinical data and microstructure of the gallbladder and liver.

Authors:  Y A EDLUND; B O MOLLSTEDT; O OUCHTERLONY
Journal:  Acta Chir Scand       Date:  1959-05-15

3.  Antibiotic tissue concentrations: methodological aspects and interpretation of results.

Authors:  O Cars; S Ogren
Journal:  Scand J Infect Dis Suppl       Date:  1985

4.  Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid.

Authors:  R A Walstad; K B Hellum; S Blika; L G Dale; T Fredriksen; K I Myhre; G R Spencer
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

5.  Simultaneous comparison of three methods for assessing ceftazidime penetration into extravascular fluid.

Authors:  D M Ryan; B Hodges; G R Spencer; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

6.  The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers.

Authors:  S M Harding; A J Monro; J E Thornton; J Ayrton; M I Hogg
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

7.  Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.

Authors:  R N Jones; A L Barry; C Thornsberry; E H Gerlach; P C Fuchs; T L Gavan; H M Sommers
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

8.  Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.

Authors:  I Phillips; C Warren; K Shannon; A King; D Hanslo
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

9.  Comparative study of the effects of ceftazidime compared with tobramycin plus cefamandole in the treatment of gall bladder empyema.

Authors:  H Schoengut; R Jelinek
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

10.  The evaluation of ceftazidime in the treatment of bacterial infections in eighty seriously ill patients.

Authors:  R A Walstad; K B Hellum; P L Svarva; P M Ingram
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

View more
  5 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

3.  Pharmacokinetics and tissue concentrations of ceftazidime in burn patients.

Authors:  R A Walstad; L Aanderud; E Thurmann-Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy.

Authors:  R A Walstad; K Dahl; K B Hellum; E Thurmann-Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Role of cephalosporins in the era of Clostridium difficile infection.

Authors:  Mark H Wilcox; James D Chalmers; Carl E Nord; Jane Freeman; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2016-09-22       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.